Barclays PLC Kymera Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 91,755 shares of KYMR stock, worth $3.63 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

91,755

Previous 91,755 -0.0%

Holding current value

$3.63 Million

Previous $4.34 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$30.16 - $52.4 $1.29 Million - $2.24 Million	42,662 Added 86.9%	91,755 $4.34 Million
Q2 2024 Aug 14, 2024	SELL	$29.85 - $39.42 $8.08 Million - $10.7 Million	-270,808 Reduced 84.65%	49,093 $1.47 Million
Q1 2024 May 15, 2024	SELL	$22.9 - $43.57 $1.42 Million - $2.7 Million	-61,880 Reduced 16.21%	319,901 $12.9 Million
Q4 2023 Feb 15, 2024	SELL	$10.97 - $26.84 $84,414 - $206,533	-7,695 Reduced 1.98%	381,781 $9.72 Million
Q3 2023 Nov 07, 2023	BUY	$13.9 - $23.88 $62,452 - $107,292	4,493 Added 1.17%	389,476 $5.41 Million
Q2 2023 Aug 03, 2023	BUY	$22.4 - $34.92 $561,232 - $874,920	25,055 Added 6.96%	384,983 $8.85 Million
Q1 2023 May 04, 2023	SELL	$24.84 - $38.75 $763,134 - $1.19 Million	-30,722 Reduced 7.86%	359,928 $10.7 Million
Q4 2022 Feb 13, 2023	BUY	$19.57 - $30.92 $736,927 - $1.16 Million	37,656 Added 10.67%	390,650 $9.75 Million
Q3 2022 Nov 03, 2022	BUY	$20.91 - $34.27 $2.51 Million - $4.11 Million	119,857 Added 51.41%	352,994 $7.69 Million
Q2 2022 Aug 12, 2022	BUY	$14.13 - $42.55 $3.2 Million - $9.63 Million	226,360 Added 3340.12%	233,137 $4.59 Million
Q1 2022 May 16, 2022	BUY	$35.3 - $64.68 $239,228 - $438,336	6,777 New	6,777 $287,000

Others Institutions Holding KYMR

# of Institutions

181

Shares Held

64.3M

Call Options Held

50.6K

Put Options Held

81.7K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.17B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account